



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70		A1	(11) International Publication Number: WO 99/25858 (43) International Publication Date: 27 May 1999 (27.05.99)
<p>(21) International Application Number: PCT/CA98/01064</p> <p>(22) International Filing Date: 13 November 1998 (13.11.98)</p> <p>(30) Priority Data: 60/065,791 14 November 1997 (14.11.97) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue West, North York, Ontario M2R 3T4 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thornhill, Ontario L4J 3E5 (CA).</p> <p>(74) Agent: STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: ALPHA VIRUS VECTORS FOR PARAMYXOVIRUS VACCINES</p> <p>(57) Abstract</p> <p>A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed <i>in vivo</i>. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) 10 protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe 15 respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full 20 bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that 25 there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children 30 with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

2

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the 5 incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in 10 clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important 15 for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotentiation. Enhanced histopathology observed in mice that were immunized with 20 the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope 25 glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F_0) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F_2 and C-terminal F_1 moieties (ref. 11). The amino acid 30 sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The 5 recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial 10 results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine 15 demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later became infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with 20 significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus 25 (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The 30 HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing *in vitro*. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA

replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex. 5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA 10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a 15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in 20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore, 25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotentiation, could be avoided by plasmid DNA immunization.

30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and

the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved
30 vectors for in vivo administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentiation).

SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by 10 respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present 15 invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; a 20 second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for 25 replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the 30 vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the 5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The 10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G 15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral 20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, *in vivo*, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein. 25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit β -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO 30 96/040945).

10

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third 5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by *in vivo* expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In 15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective 20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G 25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the 30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

11

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

12

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the 5 vectors described herein.

BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of 10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after 15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for 20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization 5 using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to 10 employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F 15 or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of 20 the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of 25 a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

30 A vector is constructed to contain a first DNA sequence which is complementary to at least part of an

14

alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as
15 metallothioneine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.
20 Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit β -
30 globin Intron II sequence may provide such splice sites, as also described in ref. 37.

15

Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early 5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of 10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397 15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the 20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a 25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively, 30 vectors containing the fourth nucleotide sequence may be

16

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, 10 that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

15 **1. Vaccine Preparation and Use**

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a 20 subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide 25 administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as 30 described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an 5 intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which 10 assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable 15 time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety 20 of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 25 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8- 30 hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This 5 delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are 10 compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, 15 or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site 20 with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to 25 mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, 30 polyalkalene glycols or triglycerides. Oral formulations may include normally employed incipients,

19

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1 µg to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

20

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5 The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH
10 10 antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

2. Immunoassays

The RSV F or G genes and vectors of the present invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the
15 15 vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,
20 20 such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may
25 25 be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the
30 30

21

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed

22

at that time. Non-viable deposits will be replaced. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration 5 of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of this invention.

Deposit Summary

	<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
10	pMP37	97905	Feb. 27, 1997
	pMP42		

EXAMPLES

The above disclosure generally describes the 15 present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and 20 substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

25 Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

EXAMPLE 1

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in
5 Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The β -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid
10 pIIIE. Plasmid pIIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATAACGACGCCAAAGATTGTTCCAGCT
CCTGCCACCTCCGCTACCGAGAGATTAACCACCCACGATGGCCGCCAAAGT
15 GCATGTTGATATTGAGGCTGACAGCCCATTCAAGTCTTGAGAAGGCA
TTTCCGTCGTTCGAGGTGGAGTCATTGCAGGTACACCAAATGACCATGCAA
ATGCCAGAGCATTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from
pSFV1 with primers SAL-SFV having the nucleotide
20 sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:
5) and ECO-SFV having the nucleotide sequence 5'
TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The resulting plasmid pMP38 was then restricted with EcoRV and BamHI and then dephosphorylated. Plasmid pSFV1
25 link (see copending application no. _____ (b/o
1038-766)) was then restricted with SpeI and ligated to the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and
3). The ligation reaction was then restricted with EcoRV to release most of the SFV-RSVF plus ribozyme
30 fragment. This fragment was then ligated to EcoRV/BamH1 restricted pMP38 to produce pMP41.

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then 5 made blunt-ended with T4 DNA polymerase. The β-globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the 10 nucleotide sequence:

TCGACATGGCGGATGTGTGACATAACAGACGCCAAAGATTTGTTCCAGCT
CCTGCCACCTCCGCTACCGAGAGATTAAACCACCCACGATGGCCGCCAAAGT
GCATGTTGATATTGAGGCTGACAGCCCATTCAAGTCTTGAGAAGGCA
TTTCCCGTCTCGAGGTGGAGTCATTGCAGGTACACCAAATGACCATGCAA
15 ATGCCAGAGCATTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from pSFVI with primers SAL-SFV having the nucleotide sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 5) and ECO-SFV having the nucleotide sequence 5'-
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The resulting plasmid pMP38 was then restricted with EcoRV and BamHI and then dephosphorylated. Plasmid pSFV1 link (see copending application no. _____ (b/o 1038-766)) was then restricted with SpeI and ligated to 25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and 3).

The ligation reaction product was then restricted with EcoRV to release the SFV replicon plus the ribozyme having the nucleotide sequence as outlined in 30 Figures 6A to 6C. This fragment was then ligated to the EcoRV/BamHI restricted pMP38 to produce pMP42. The

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to
5 3E.

EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by
10 the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB/C mice were bilaterally injected with 2 x 100 µg of plasmid pMP44. This amount is equivalent to approximately 94µg of a conventional vector, based on copy number. These mice were boosted
15 in an identical manner 4 weeks later. The control group was immunized with 2 x 25 µg of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The
20 immunization protocol is set forth in the following

Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA ¹	Intramuscular	SFV-RSVF RNA ¹	Intramuscular
	2 pMP44 DNA ²	Intramuscular	pMP44DNA ²	Intramuscular

Mice were inoculated with:

1. 25µg of RNA was injected into each hind leg muscle in 50 µL of PBS
- 30 2. 100 µg of DNA was injected into each hind leg muscle in 50µL of PBS

Sera was obtained from the mice at 4 and 6 weeks.

Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with 10^6 plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete 15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and 25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre (log ₁₀ /g±s.d) % Protection	
	Prime	Boost		
30	1 SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
	2 pMP44 DNA	pMP44DNA	2.12*	83

* Limit of detection = 1.8

EXAMPLE 4

This Example describes the determination of anti-
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific binding by adding 0.1% BSA in PBS for 30 min. at room 10 temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room 15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab'), goat antimouse IgG (H+L specific)- HRP from Jackson 20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay. 25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was 30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

28

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of 10 immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). *Virology*. Raven Press, New York, 1990, pp.1045-1072.
- 5
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., *Virus Res* 32, 13-36, 1994.
- 10
3. Osterweil D. and Norman D., *Am Geriat Soc* 36, 659-662, 1990.
- 15
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., *J Med Virol* 30, 117-127, 1990.
- 20
5. Katz S.L. in *New vaccine development establishing priorities Vol 1*. National Academic Press, Washington, 1985, pp. 3974 09.
6. Wertz G.W. and Sullender W.M., *Biotechnology* 20, 151-176, 1992 .
- 25
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., *Am J Epidemiol* 89, 449-463, 1969.
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., *Am J Epidemiol* 89, 449-463, 1969.
- 30
9. Belshe R.B., Van Voris L.P. and Mufson M.A., *J Infect Dis* 145, 311-319, 1982.
- 35
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., *Pediatrics* 48, 745-755, 1971.
- 40
11. Gruber C. and Levine S., *J Gen Virol* 64, 825-832, 1983.
12. Olmstead R.A., Elango N. and Prince G.A., *Proc Natl Acad Sci USA* 83, 7462-7466, 1991.

13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasyshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
- 20 17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 25 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 30 20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 35 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
- 40 22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.

25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) *J. Infect. Dis.* 157 (4), 648-654.

5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) *J. Infect. Dis.* 162, 746-749.

10 27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) *J. Virol.* 62 (3), 783-787.

28. Ewaszshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) *Vaccine* 10 (6), 412-420.

15 29. Ambrose, M.W., Wyde, P.R., Ewaszshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) *Vaccine* 9, 505-511.

20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. *J. Virol.* 1984; 52:828-32.

31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) *J. Gen. Virol.* 74, 459-469.

25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) *J. Gen. Virol.* 74, 471-477.

30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) *Vir. Res.* 24, 21-33.

34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) *Vaccine* 9, 659-667.

35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). *The Togaviridae and Flaviviridae.* Plenum Press, New York, 1986, pp.35-90.

40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., *Nucl. Acids. Res.* 1991, 19: 3979-3986.

45 37. Breathnack, R. and Harris, B.A., *Nucl. Acids Res.* 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90: 11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205: 365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790, 1978.

CLAIMS

What we claim is:

1. A vector, comprising:

5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
10 a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
15 under transcriptional control of a promoter.

2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV).

20
3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4

25

4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

34

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.

5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.

7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G 10 protein lacking the transmembrane anchor and cytoplasmic tail.

8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.

15

9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.

20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.

11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence 25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed *in vivo* from the vector in a host.

12. The vector of claim 11 wherein the third nucleotide 30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, *in vivo* whereby substantially

35

all transcribed mRNA from the vector region administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide sequence is located between the first nucleotide sequence and the promoter sequence.

14. The vector of claim 13 wherein said third nucleotide sequence is that of rabbit β -globin intron 10 II.

15. The vector of claim 10 wherein said promoter sequence is an immediate early cytomegalovirus (CMV) promoter and the human cytomegalovirus Intron A sequence is provided downstream of the promoter and upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth nucleotide sequence at the 3'-end of the first nucleotide sequence to ensure proper *in vivo* cleavage at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth nucleotide sequence is a hepatitis delta virus ribozyme sequence.

18. The vector of claim 1 which has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID NO: 1.

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 20 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isолating said gene;
20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and
introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

5 26. The method of claim 25 including the step of:

operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

15

28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit β -globin intron II.

25

30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30

32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isолating a first DNA sequence encoding an RSV or G 5 protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete 10 alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

15 formulating the vector as a vaccine for *in vivo* administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 20 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

25 35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

39

37. The composition of claim 36 wherein said vector has
the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 SEQ ID no: 1.

1/16

41
Figure 4 Construction of pMP44




Fig. 4a 1a





Fig 13



+ Bam H I fragment
from pMP37

Lm12

↓

Fig 1c




FIG 10

5/16


Figure 1 Construction of pMP44

FIG. 2A




Figure 3 Nucleotide sequence of plasmid pMP44

tcgcgcgttt cggtgatgac ggtaaaaacc tctgacacat gcagctccc gagacggtca 60
 caacctgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcggttg 120
 ttggcggttg tcggggctgg cttaactatg cggcatcaga gcagattgtt ctgagagtgc 180
 accatatgcg gtgtaaaata ccgcacagat gcgttaaggag aaaataccgc atcagattgg 240
 ctattggcca ttgcatacgt tgatccata tcataatatg tacatttata ttggctcatg 300
 tccaaacatta cggccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
 ggggtcatta gttcatagcc catatatggg gttccgcgtt acataactta cggtaaatgg 420
 cccgcctggc tgaccgccc accgaccccg cccattgacg tcaataatga cgtatgttcc 480
 catagtaacg ccaataggga cttccattg acgtcaatgg gtggagtatt taacggtaaac 540
 tgeccacttg gcagtcacatc aagtgtatca tatgccaatg acgcccccta ttgacgtcaa 600
 tgaeggtaaa tggccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
 ttggcgtac atctacgtat tagtcatcgc tattaccatg gtatgcggg tttggcagta 720
 catcaatggg cgtggatgc ggtttgactc acggggattt ccaagtctcc accccattga 780
 cgtcaatggg agtttgttt ggacccaaaa tcaacggac tttccaaaat gtcgtaacaa 840
 ctccgccttca ttgacgcaaa tggcggttag gctgtacgg tgggagggtct atataagcag 900
 agtcgtttt gtgaaccgtc agatcgctg gagacgcctt ccacgcgttt ttgaccttcca 960
 tagaaagacac cgggaccgtt ccagcctccg cggccggaa cgggcattt gaaacgcggat 1020
 tccccgtgcc aagagtgcg taagtaccgc ctatagactc tataggcaca cccctttggc 1080
 tcttatgcat gctatactgt ttttggcttg ggcctatac accccggctt ctttatgtcta 1140
 taggtgtatgg tatacttagtgc cctataggtt tgggttattt accattatgg accacttccc 1200
 tattgggtgac gatactttc attactaatc cataacatgg ctcttgcacca caactatctc 1260
 tattggcttat atgccaatac tctgtccttc agagactgac acggactctg tattttaca 1320
 ggtatgggtc ccatttata ttacaaattt cacatataca acaacgcgtt ccccccgtgcc 1380
 cgcaagtttt attaaacata gctgtggatc tccacgcgaa tctcgggtac gtgtccggaa 1440
 catgggtct tctccgttag cggcggagct tccacatccg agccctggtc ccatgcctcc 1500
 agcggctcat ggtcgtcgg cagtccttg ctccataacag tggaggccag acttaggcac 1560
 agcacaatgc ccaccaccac cagtgtgcgg cacaaggccg tggcggtagg gtatgtgtct 1620
 gaaaatgagc gtggagattt ggctcgacg gctgacgcag atggaaagact taaggcagcg 1680
 gcagaagaag atgcaggcag ctgagttgtt gtattctgtt aagagtcaaa ggttaactccc 1740
 gttgcgtgc tgtaacggt ggagggcagt gtagtcttag cagtaactgt tgcgtccgcg 1800
 cgcgcacca gacataatag ctgacagact aacagactgt tcccttccat ggttctttc 1860
 cgatccgtatg aacttcaggg tgagtttggg gacccttgc tggttttct ttttgcgtat 1920
 tgtaaaaattc atgttatatg gggggggcaaa agttttcagg gtgttgttta gaatggaaag 1980
 atgtcccttg tattaccatg gacccttcattt gataattttgtt ttcttcaact ttctactctg 2040
 ttgacaacca ttgtctccctt ttatttttttt ttcatttttt gtaatttttt cgttaaactt 2100
 tagtttgcattt tgtaacgaa tttttaaattt cactttttttt tatttgcattt attgtaagta 2160
 ctttctttaaa tcaactttttt ttcaaggcaaa tcagggtata ttatattgtt ctteagcaca 2220
 gtttttagaga acaattgttta taattaaatg ataaggtaga atatttctgc atataaaattc 2280
 tggctggcgtt gggaaatattt ttatggtag aaacaactac atccgttca tcatcctgcc 2340
 ttctctttaa tggttacaat gatataactt gtttggatgtt aggataaaat actctgatgc 2400
 caaaccgggc cccttcgttca accatgttca tgccttcctt ttttcttac agctcctggg 2460
 caacgtctg gttattgtgc tgctctatca ttttggcaaa gaattgttac gacactcact 2520
 atagggcggaa ttgtcaccgt cgtcgacatg gggatgtgtt gacatacagc acggccaaag 2580
 attttgccttcc agctcctgcc accctccgttca cgcgagagat taaccaccca cgatggccgc 2640
 caaagtgcattt gttgatattt ggggttgcacag cccatttcattt aagtcttgc agaaggcatt 2700
 tccgtcttc gaggtggagt cattgcaggat cacaccaat gaccatgcaa atgcccagagc 2760
 attttgcac ctggcttacca aattgtatca gcaaggagact gacaaagaca cacttcattt 2820
 ggatatgcgc agtgcgcctt ccaggagaat gatgtctacg cacaatacc actgcgtatg 2880
 ccctatgcgc agcgcacaaag accccggaaag gctcgatagc tacgcaaaaga aactggcagc 2940
 ggcctccggg aaggtgttgg atagagagat cgcaggaaaa atcaccgacc tgcagacccgt 3000
 catggctacg ccagacgcgtt aatctccatc ttttgccttgc catacagacg tcacgtgtcg 3060
 tacggcaggcc gaaatggccg tataccagga cgtgtatgtt gtacatgcac caacatcgtt 3120
 gtaccatca gcgatgaaag gtgtcagaac ggcgtatttttgg attgggtttt acaccacccc 3180
 gtttatgtttt gacgcgttag caggcgcgtt tccaaacctac gccacaaaact gggccgacga 3240

7.34

cgagggttta caggccagga acataggact gtgtgcagca tccttgactg agggaaagact 3300
cggcaactg tccattctcc gcaagaagca attgaaacct tgcgacacag tcatgttctc 3360
ggtaggatct acattgtaca ctgagagcag aaagctactg aggagctggc acttaccctc 3420
cgattccac ctgaaaggta aacaatccc tacctgttagg tgcgatacca tctgtatcatg 3480
tgaagggtac gttagtaaga aaatcactat gtgccccggc ctgtacggta aaacggtagg 3540
gtacgcccgt acgtatcagc cgaggaggatt cctagtgtgc aagaccacag acactgtcaa 3600
aggagaaaaga gtctcattcc ctgtatgcac ctacgtcccc tcaaccatct gtatcaa 3660
gactggcata ctacgcaccc acgtcacacc ggaggacgea cagaaggttgt tagtgggatt 3720
gaatcagagg atagttgtga acggaagaac acagcggaaac actaacacga tgaagaacta 3780
tctgttccg attgtggccg tcgcatttag caagtggcg aggaaataca aggcagacct 3840
tgatgtgaa aaacctctgg gtgtccgaga gaggtcaett acttgtctgt gtttggg 3900
attnaaacg aggaagatgc acaccatgt acaagaaacca gacacccaga caatagtga 3960
ggtgcctca gagtttaact cgttcgtcat cccgagccta tggtctacag gcctcgeaat 4020
cccagtcaga tcacgcatta agatgtttt gccaagaag accaagcggag agttaatacc 4080
tgttctcgac gctgcgtcag ccagggatgc tgaacaagag gagaaggaga gtttggag 4140
cgagctgact agagaaggct taccacccct cgtccccatc gcgcggcgg agacgggagt 4200
cgtegacgtc gacgttgaag aactagaga tcacgcaggt gcaggggtcg tggaaacacc 4260
tcgcagcgcg ttgaaagtca cccgacagcc gaacgacgta ctactaggaa attacgttagt 4320
tctgtccccg cagaccgtgc tcaagagctc caagtggcc cccgtgcacc ctctagcaga 4380
gcaggtgaaa ataataaacac ataacgggg ggcggcggt taccaggtc acggatata 4440
ccgcagggtc ctactaccat gtggatcggc cattccggc cctgaggta aagcttttag 4500
cgagagcgc actatgggt acaacgaaag ggagttcgtc aacagggaaac tataccat 4560
tgccgttccac ggacgtcgc tgaacaccga cgaggagaac tacagaaaaag tcagagctga 4620
aagaactgac gccgagtagc agctcggtt ttgggttgg tggagagct agataaaaaa tgctgcgtca agagagagga 4680
cgaagggtg aagatcaggc ctgcttattt taagagcctc gtgaccaaaac acgtatctgtt 4740
ggttccggga tcaggcaagt actgccagga aatagttaac gacgtgaaga acgcacccgg 4920
caccagccgc aagaaggaga acagtgactc catectgcta aacgggtgtc gtcgtccgt 4980
gaaggggaca agtagggaaa ggacatccct tatgtggacg aggcttcgc ttgcattcc ggtactetgc tggccctaa 5040
tgctttgtt aaacctcgga cttaatatg atgcagctt gcaaagtgtt gttatgcggg gaccccaagc aatgcggatt 5100
taaaagtata tccagacgtt cggaggaag atgcgcacga acagaccaag cccaaagccag aggtgaactt caaccacaac atctgcactg aagtatgtca 5160
ccgaaagggtt gtatacgccg gctgcagggt gactaccgtg cgcacgcgtcc agtcaacggcc atctgtgtca cgttgcacta 5220
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag cccaaacccgtg caacaaaccc ataatcataa acaccacagg 5280
gctgcagggtt gactaccgtg aacacgacaa aataatgtaa gtttggatgg gacacatcg tttccggaggt gggcaaaagca 5340
ccgaaagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 5400
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 5460
gctgcagggtt gactaccgtg aacacgacaa aataatgtaa gtttggatgg gacacatcg tttccggatgtt gggccatcc 5520
ccgaaagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 5580
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 5640
gctgcagggtt gactaccgtg aacacgacaa aataatgtaa gtttggatgg gacacatcg tttccggatgtt gggccatcc 5700
ccgaaagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 5760
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 5820
gctgcagggtt gactaccgtg aacacgacaa aataatgtaa gtttggatgg gacacatcg tttccggatgtt gggccatcc 5880
ccgaaagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 5940
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6000
gctgcagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 6060
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6120
gctgcagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 6180
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6240
gctgcagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 6300
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6360
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6420
gctgcagggtt gtatacgccg gctgttccaga cttggacact gccggaaatca taaggcagaa ggtgaatgaa aatccctgtt atccccctgc 6480
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6540
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6600
gtcgaggacat gtgaaatgtac ggcggcgat ccctggatta attggaaagaa tggcaagaag gacacgaaatccaa cttccggatgtt gggccatcc 6660

agcagacata gcccgtgca cagaagcggc tgggttaac gcagctaactg cccgtggaa^c 6720
 tgttagggat ggcgtatgca gggccgtggc gaagaaaatgg cctgttgcgc ttaaggggagc 6780
 agcaacacca gtgggcacaa taaaacagt catgtgcggc tctgttcccg tcattccacgc 6840
 tgttagcgcct aattttctgt ccacgactga aecggaaagg gaccgcgaat tggccgctgt 6900
 ctacccggca gtggccgccc aagtaaacag actgttactg aecgagcgtg ccatccccgt 6960
 gctgtccaca ggagtgttca gggccggaa agataggctg cagcaatccc tcaaccatct 7020
 attcacagca atggacgcca cggacgctga cgtgaccate tactgcagag aaaaaagttg 7080
 ggagaagaaa atccaggaag ccattgacat gaggacggt gtggagttgc tcaatgtga 7140
 cgtggagctg accacagact tggtgagagt gacccggac aecgagcctgg tgggtcgtaa 7200
 gggctacagt accactgacg ggtcgctgtc ctcgtacttt gaaggtacga aattcaacca 7260
 ggctgttattt gatatggcag agataactgac gtttgtggcc agactgcag aggcaaacga 7320
 acagatatgc ctatacgcge tggggcaaaac aatggacaac atcagatcca aatgtccgg 7380
 gaacgattcc gattcatcaa cacccccag gacagtgc tgcctgtgc gctacgcata 7440
 gacagcagaa cggatcggcc gccttaggtc acaccaagt aaaagcatgg tgggttgc 7500
 atcttttccc ctccggaaat accatgtaga tgggggtgcag aaggtaaaagt gcgagaagg 7560
 tctctgttc gacccgacgg taccttca gtttgcgttcc cggaatgtt cccgcattac 7620
 gacggaccac tcagatcggt cgttacgagg gtttgcgtt gactggacca cccgactcg 7680
 ttccactgccc aegegatacca tgcgttccgat cagtttgcag tctgttgaca tgcactcgat 7740
 ctacgagcca atggcttcca tagtagtgc ggtgtacgttcc cccctgttcc 7800
 cggggacctg ggggcagatg tgccatccgat aecggcagac catgtggacc tcgagaaccc 7860
 gatttccca cccggccccc agagactgc ataccttgc tcccgccgg cggagcggacc 7920
 ggtggccggc cccggagaaagc cggacgctgc cccaaaggact gctgttagga acaagctgc 7980
 tttgaegtcc ggcgactttt acgagcacga ggtcgatgc ttggctccg ggattactt 8040
 cggagactt gacgacgtcc tgcgtacttgg cccgcgggt gcatatatattt tctctcgga 8100
 caetggcagc gggacattac aacaaaaatc cgtttaggcag cacaatctcc agtgcgcaca 8160
 actggatgcg gttcaggagg agaaaaatgtt cccggccaaa ttggatactg agagggagaa 8220
 gtttgtctg ctgaaaatgc agatgcaccc atcgaggact aataagatc gataccagtc 8280
 tcgcaagtg gagaacatga aagccacggt ggtggacagg ctcacatcg gggccagatt 8340
 gtacacggga gccggacgttgc gccgcatacc aacatacgc gttcggtacc cccggccgg 8400
 gtactccctt accgttgcataa aaagatttcc aagccggat gtagaaatcg cagcgtgca 8460
 cgaataaccta tccagaaattt acccaacagt ggcgtcgatc cagataacag atgaatacga 8520
 cgcatactt gacatgggtt acgggtcgga tagttgttgc gacagagcga cattctggcc 8580
 ggcgaagctc cggtgetacc cggaaacatca tgcgttccac cagccgactg taecgcgtgc 8640
 cgtcccgatcc cccttcaga acacactaca gaacgtgttgc gggccggca ccaagagaaa 8700
 ctgcaacgtc acgcaaatgc gagaactacc caccatggc tggcgtgttgc tcaacgttgg 8760
 gtgttcaag cgttatgc tgcctggaga atattggaa gatattgttca aacaacctat 8820
 ccggataacc actgagaaca tcaactacca tggatggatc ttggacccaa ttggacagatt 8880
 tgccttgc tcaatggacc acaacttggt tccgtcgatc gaggttccca tggacagatt 8940
 cacggtcac atgaaacgg atgttcaatggt cactccaggc acggaaacaca cagagggaa 9000
 acccaaaatgc caggtaatcc aaggcgggatc gccattggcg accgttacc tgcgtggccat 9060
 ccacaggaa tttagtaagga gactaaatgc tggatggatc ctttttttttgc acatattttt 9120
 tgatatgtcg gccggacact ttgtacgttgc catcgcttcc cacttccacc caggagacc 9180
 ggttcttagag acggacattt ctttttttttgc acatcgatcc tggatggatc tggatggatc 9240
 aggtttatgg atcctcgatc atcttagggatc ggttcttagatc tggatggatc tggatggatc 9300
 agcctttggg gaaatatcca gctgttccatc accaactggc acggcgttca agttcgaggc 9360
 tatgtatggaa tggggatc ttttttttttgc ttttttttttgc acatcgatcc tggatggatc 9420
 agcaagcgg gtttttttttgc agagacttcc tggatggatc tggatggatc tggatggatc 9480
 cgacaacatc gtccacggatc tggatggatc tggatggatc tggatggatc tggatggatc 9540
 ggtcaacatc gggatggatc tggatggatc tggatggatc tggatggatc tggatggatc 9600
 tggggatc tggatggatc tggatggatc tggatggatc tggatggatc tggatggatc 9660
 taagcgccatc ttcaatggatc tggatggatc tggatggatc tggatggatc tggatggatc 9720
 gggatggatc tggatggatc tggatggatc tggatggatc tggatggatc tggatggatc 9780
 ggaggtggca ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9840
 gggccacccatc gggatggatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9900
 ctacggcggt ctttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 9960
 attataggat cccggccgc gaaatccggatc ctttttttttgc ttttttttttgc ttttttttttgc 10020
 gcaatgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 10080

atcactgaag aattttatca atcaacatgc agtgcaggtt gcaaaggcta tcttagtgct 10140
 ctgagaactg gttggatac cagtgttata actatagaat taagtaatat caaggaaaat 10200
 aagtgtaatg gaacagatgc taaggtaaaa ttgataaaaac aagaattaga taaatataaa 10260
 aatgtctgtaa cagaattgca gttgctcatg caaagcacac cagcagcaaa caatcgagcc 10320
 agaagagaac taccaggat tatgaattat acactcaaca atgccaaaaaa aaccaatgtta 10380
 acattaagca agaaaagaa aagaagattt cttggtttt tgtaggtgt tgatctgca 10440
 atcgccagtg gcgttgcgt atctaaggtc ctgcacccat aaggggaaat gaacaagatc 10500
 aaaagtgtctc tactatccac aaacaaggct gtatgcgt tatcaatgg agttagtgctc 10560
 ttaaccagca aagtgttaga cctcaaaaac tatagata aacaattgtt acctattgtg 10620
 aacaaggcaaa gctgcagcat atcaaatata gaaactgtga tagaggcata aaaaaagaac 10680
 aacagactac tagagattac cagggattt agtgttaatg caggttaac tacacctgt 10740
 agcacttaca tggtaactaa tagtgaatta ttgtcattaa tcaatgatat gcttataaca 10800
 aatgtatcaga aaaagttaat gtccaaacaat gttcaaatacg ttagacagca aagttactct 10860
 atcatgttca taataaaaaga ggaagtctta gcatatgtatg tacaattacc actatatgg 10920
 gttatagata caccctgtt gaaactacac acatccccctc tatgtacaac caacacaaaa 10980
 gaagggttcca acatctgtt aacaagaact gacagaggat ggtactgtga caatgcagga 11040
 tcagttatctt tcttccca agctgaaaca tgtaaagttc aatcaatcg agtattttgt 11100
 gacacaatga acagtttaac attaccaagt gaaataaaatc tctgcaatgt tgacatattc 11160
 aaccccaaat atgattgtaa aattatgact tcaaaaaacag atgtaagcag ctccgttattc 11220
 acatctctag gagccattgt gtcatactat ggcaaaaacta aatgtacagc atccaataaa 11280
 aatcgtggaa tcataaaagac attttctaaac gggtgcgatt atgtatcaaa taaaagggtat 11340
 gacactgtgt ctgttaggtaa cacattataat tatgtaaata agcaagaagg taaaagtctc 11400
 tatgtaaaag gtgaaccat aataaaatttc tatgaccat tagtattccc ctctgtatgaa 11460
 tttgatgcat caatatctca agtcaacgag aagattaacc agagcctagc atttattcgt 11520
 aaatccgtat aattattaca taatgttaat gctggtaaat ccaccacaaa tatcatgact 11580
 tgataatgag gatccagatc ccgggttaatt aattgaatta catccctacg caaacgtttt 11640
 acggccgcccgttggccccc cgccggccgg tgctcccgat cgtcccccac ttccaggcccc 11700
 atgcgtgtac aatgagacag aaccaatttgc gctctgtatc gctcccccac ccaaagaaga 11760
 agaagacaac caaaccaaaag ccggaaaacgc agcccaagaa gatcaacggaa aaaacgcagc 11820
 agcaaaaagaa gaaagacaag caagccgaca agaagaagaa gaaacccgga aaaaagagaaa 11880
 gaatgtgcat gaagattgaa aatgactgtat tcttcgtatg cggctagcca cagtaacgt 12000
 gtgtttccag acatgtccggg caccgcacta tcatgggtgc agaaaatctc ggggtggctg 12060
 gggcccttcg caatcgccgc tatectggtg ctgggtgttgcacttgcat tgggctccgc 12120
 agataagttt gggtaggcaaa tggcattgtat agataagggaa aattaaaaac agaaaaaaatgt 12180
 agggtaagca atggcatat accataacttgc tataacttgc aacaaagcgc aacaagacct 12240
 ggcgaatttgg cccctgttgc cgcctcacgg aacactcccccaactcatat tgacacattt 12300
 attggcaata attggaaacttacataatgcg taattcgacg aataatttggaa tttttat 12360
 attttgcaat tggttttaa tatttccaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa 12420
 aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa 12480
 cacctccctcg cggtccgacc tggcattccg aaggaggacg cacttccact cggatggct 12540
 agggagagat ccagatctgc tggccttctc agttggccacg catctgttgc tggccctcc 12600
 cccctgttgc ctttgcaccctt ggaagggtgcc actcccaactg tccttccata ataaaatgag 12660
 gaaatttgcat cgcattgtct gaggtaggtgtt catttcttgc tgggggttgg ggtggggcag 12720
 gacagcaagg gggaggattt ggaagacaat agcaggcatg ctggggatgc ggtgggctct 12780
 atgggtaccc aggtgtgtaa gaatttgcacc gtttccctct gggccagaaaa gaagcaggca 12840
 catcccccttc tctgtgacac accctgtcca cggccctgttgc tcttagttcc agccccactc 12900
 ataggacact catacgatcg gagggtccgc ctttcaatcc caccgcataa agtacttgg 12960
 ggggtctctc cttccctcat cagcccaacca aacccaaacct agcctccaag agtgggaaga 13020
 aattaaagca agataggctt ttaagtgtcag agggagagaa aatgcctcca acatgtgagg 13080
 aagtaatgag agaaatcata gaatttcttc cgttccctcg ctcactgact cgctgcgcctc 13140
 ggtcggttcgg ctgcggcgag cggatcgc tcactcaaag gggtaatac gtttatccac 13200
 agaattcaggg gataacgcag gaaagaaat gtgagcaaaa ggccagcaaa aggccaggaa 13260
 ccgtaaaaag gcccgttgc tggcgtttt ccataggctc cgcctccctg acgagcatca 13320
 caaaaatcgca cgctcaagtc agagggtggcg aaacccgaca ggactataaa gataccaggc 13380
 gtttccctt ggaagctccc tcgtgcgtc tctgttccg accctgcgc ttacccgata 13440
 cctgtccgccc tttctccctt cgggaaagcgt ggcgccttct ctagctcac gctgttaggt 13500

11/16

tctcagttcg gtgttaggtcg ttgcgtccaa gctgggctgt gtgcacgaac cccccgttca 13560
gcccggaccgc tgccgccttat ccggtaacta tcgtcttgag tccaaacccgg taagacacgga 13620
cttatacgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgttaggcgg 13680
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatgg 13740
tatctgcgt ctgtctgaagc cagttacett cgaaaaaaaaga gttggtagct cttgtatccgg 13800
caaacaacc accgctggta gccgggtgttt ttttgggtgc aagcagcaga ttacgcgcag 13860
aaaaaaaaaggaa tctcaagaag atccctttgat cttttctacg gggctctgacg ctcagtggaa 13920
cgaaaactca cgtaaggga ttttggtcat gagattatca aaaaggatct tcaccttagat 13980
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 14040
tgacaggtaa caatgttca tcagtggagc acctatctca gcatctgtc tatttcgttc 14100
atccataggat gctgtactcg ggggggggggg ggegtggaggt ctgcctctg aagaagggt 14160
tgctgactca taccaggcct gaatcgcccc atcatccagc cagaaaagtga gggagccacg 14220
gttggatgaga gctttgtgt aggtggacca gttggtagt ttgaactttt gctttgcac 14280
ggaacgggtct gcgttgcgg gaagatgcgt gatctgatcc ttcaactcag caaaagggtcg 14340
atttattcaa caaagccgc gtcggctcaa gtcagcgtaa tgctctgcca gtgttacaac 14400
caattaacca attgtgatta gaaaaactca tcgagcatca aatgaaaactg caatttattc 14460
atatcaggat tatcaatacc atattttga aaaagccgtt tctgtaatga aggagaaaaac 14520
tcaccggaggc agttccatag gatggcaaga tcctggatc ggtctgcat tccgactcg 14580
ccaacatcaa tacaacctat taatttcccc tcgtcaaaaaa taaggttate aagtggaaaa 14640
tcaccatgag tgacgactga atccgggtgag aatggcaaaa gcttgcatt ttctttccag 14700
acttgttcaa caggccagcc attacgttc tcatcatttc cactcgcatc aaccaaaccg 14760
tttattcatc gtgtatgcgc ctgagcggaga cgaaaatacgc gatcgtgtt aaaaggacaa 14820
ttacaaaacag gaatcgaatg caacccggcgc aggaacactg ccagcgcatc aacaatattt 14880
tcacctgtaa caggatattt ttcttaatacc tggaatgtc tttcccccgg gatcgcagt 14940
gtgagtaacc atgcatttcattc aggagatcgg ataaaatgtc tgatggtcgg aagaggcata 15000
aattccgtca gccaggtag tctgaccatc tcatctgtaa catcattggc aacgctacct 15060
ttgccatgtt tcagaaacaa ctctggcgca tcgggcttcc catacaatcg atagattgtc 15120
gcacccgtt gccccacatt atcgcgaccc catttatacc catataaattc agcatccatg 15180
tttggatattt atcgccgcct cgagcaagac gtttcccggtt gaatatggct cataacgttc 15240
cttgcattttc tttttatgtt agcagacagt tttattgttc atgtatgat atttttatct 15300
tgtgcataatgt aacatcagag attttggac acaacgttgc tttttttttt cccccattat 15360
tgaaggcattt atcagggtta ttgtctcatg agcggatatac tatttgaatg tattttagaaa 15420
aataaaacaaa taggggttcc ggcgcacattt cccccggaaag tgccacctga cgtctaagaa 15480
accattattt tcatgacattt aacctataaa aataggcgta tcacgaggcc ctttcgtc 15538

Fw 38

12/16

Figure 4: Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting




Figure 5 Ribozyme linker for pMP42

5' CTAAGGGGTGGCATGGCATCTCCACCTCTGGGACTCGAAGGGAGGCACGTCCACTCGGATGGCTAAGGGAGA
GCCAGCCGTACCGTAGGGTTGAGGAGCCGTAGGGCTTCCCTGCGTGAGGTGAGCCTACCGATTCCCTCTCTAG
3'

Figure 6 ASFV Eco RV-Spe I fragment ligated to ribozyme

atcggcagtgcgcctccag gagaatgatgt tctacgcaca aataccactgcgtatgc 60
 atgegcagcg cagaagaccc cgaaaaggctc gatagctacg caaagaaact ggcaeggcc 120
 tcgggaaagg tgctggatag agagatcga ggaaaaaatca ccgactgcac gacegtcatg 180
 5 getacgcgcag acgctgaatc tctacctt tgeetgcata cagacgtcag gtgttgtacg 240
 gcagccgaag tggccgtata ccaggacgtg tatgtgtac atgcaccaac atcgctgtac 300
 catcaggcga tgaaggtgt cagaacggcg tattggattt gtttgacac caccggctt 360
 atgtttgacg cgcgtatcca acctacgcac caaactggcc cgacgagcag 420
 gtgttacagg ccaggaacat aggactgtgt gcaacatct tgactgaggg aagactcggc 480
 10 aaactgttcca ttctcegcaa gaagcaattt aaacccgtcg acacagtcat gtttcggta 540
 ggtatctatcat tgcactactga gagcagaaag ctactgagga gctggcactt accctccgta 600
 ttccacactga aaggtaaaca atccttacc ttaggtgcg ataccatgt atcatgtgaa 660
 gggtacgttag ttaagaaaat cactatgtgc cccggccgt acggtaaac ggtagggtac 720
 gccgtgacgt atcacgcgga gggattccta gtgtcaaga ccacagacac tgcacaaagg 780
 15 gaaagagtctt catccctgt atgcacctac gtcaccccaa ccatctgtga tcaaattgtact 840
 ggcatactag cgacccgacgt cacacccggag gacgcacaga agttgttagt gggattgaa 900
 cagaggatag ttgtgaacgg aagaacacag cggaaacacta acacgatgaa gaactatctg 960
 ctcccgattt tggccgtcgc atttagcaag tggggcggg aatacaaggc agacccgtt 1020
 20 gatgaaaaac ctctgggtgt cegagagagg tcaacttactt gctgtgtt gttggcattt 1080
 aaaacgagga agatgcacac catgtacaag aaaccagaca cccagacaat agtgaagggt 1140
 ctttcagagt ttaactcggtt cgtcatcccg agccatgtt ctacagggct cgcaatcccc 1200
 gtcagatcac gcattaagat gctttggcc aagaagacca agcggaggtt aataccgtt 1260
 ctgcacgcgt cgtcagccag ggatgtcgaac caagaggaga aggaggggtt ggaggccgg 1320
 ctgactagag aaccccttacc acccctcgcc cccatcgccg cggccggagac gggagtcgtc 1380
 25 gacgtcgcacgt ttgttgcactt agagtatcac gcagggtcag ggggtcggtt aacacccgtc 1440
 agegcgttga aagtccgc acacccgaaac gacgtactac taggaattt cgtatgttctg 1500
 tccccgcaga cctgtctcaa gagctccaaag ttggcccccgt tgccacccctt agcagagcag 1560
 gtgaaaataaa taacacatccat cggggaggccc ggcgggttac aggtcgcacgg atatgacggc 1620
 30 agggcttccatc taccatgtgg atccggccatt cccggccctt agtttcaagc tttgagcgg 1680
 ageggccacta tgggttacaa cggaaaggag ttegtcaaca gggaaactata ccatattgcc 1740
 gttcacggac cgtcgctgaa caccggacgg gagaactacg agaaaagtcaag agctgaaaga 1800
 actgacgcgg agtacgtgtt cgacgttagat aaaaaatgtt gctgtcaagag agaggaagcg 1860
 tcgggtttgg ttttttttttgg agagctaaacc aaccccccgt tccatgaatt cgcctacgaa 1920
 gggctgaaga tcaggccgtc ggacccatata aagactacag tagtaggatg ttttgggtt 1980
 35 cccggatcaag gcaagtcgtc tatttataag agccctgtca ccaaacacga tctggtcacc 2040
 ageggcaaga aggagaactg ccaggaaata gttaaacgacg tgaagaagca ccgcgggaaag 2100
 gggacaagta gggaaaacag tgactccatc ctgcctaaacg ggtgtcgctg tgccgtggac 2160
 atccatatatg tggacgaggc ttctcgctgc cattccggta ctctcgctggc cctaattgtt 2220
 40 cttgtttaaac ctcggagcaa agtgggttta tgcggagacc ccaagcaatg cggatttttc 2280
 aatatgatgc agttaaggtt gaaacttcaac cacaacatct gcaactgaatg atgtcataaa 2340
 agtatataccca gacgttgcac gctgtccatc acggccatcg tgcactacgg 2400
 ggcaagatgc gcacgacccaa cccgtgcacaa aaacccatata tcatgacac cacaggacac 2460
 accaageccca agccaggaga catcggttta acatgttcc gagggtggcc aaaggcgttgc 2520
 45 cagttggact accgtggaca cgaagtcatg acacggcact catctcgagg ctcacccgc 2580
 aaagggttat acggccgtaa gcaagaagggtt aatggaaatc ctttgtatgc ccctgcgttgc 2640
 gagcacgtga atgtactgtt gacggcactt gaggatggc tgggttggaa aacgctggcc 2700
 ggtgtatccct ggatgttgcactt ccttgcacaaatc atccacagg gtaactttac ggcacattt 2760
 gaagaatggc aagaagaacaa cgacaaaata atgaagggtt ttttttttttggac ggcgtggcc 2820
 gtggacgcgt tccggaaacaa agcggacgtt ttttttttttggca aaaggcttgcgttgcctt 2880
 50 gacactgcggc gaatcgattt gacacggagag gatgtggacca ccataattac agcattttaa 2940
 gaggacagag cttacttcc agtgggtggcc ttgtatggaa tttgcacccaa gtactatgg 3000
 gttgacccgtt acagtggccct gttttctgtcc cccgttgcata cggaaagggtt ccctgttata 3060
 cactgggata acagacccgtt tggaggatgt tatggatca atgcgcacac agctgcccagg 3120
 ctggaaagctt gacataccctt cctgggggg cagttggcata cggccaaacca ggcgttac 3180
 55 gcagaaaagaa aaatccaaacc gttttctgtt ctggacaatg taatccat caacccgcagg 3240
 ctgcggcactt ccctgggtgc tgactacaag acggttaaag gcaatgggtt tgactggctg 3300
 gtcaataaaag taagagggtt ccacgttccgt ctgggtggatg agtacaaccc ggcgttgcct 3360
 cgacgcaggg tcacttgggtt gtcacccgtt gatgtcacag ggcgttac gtcacccgttgcac 3420

fc.6b

ctaagtttag gactgccggc tgacgccccgc aggttcgact tggtctttgt gaacattcac 3480
 acgyaattca gaatccacca ctaccagcag ttgtcgacc acgcctatgaa gctgcagatg 3540
 cttggggagg atgcgcgtacg actgtctaaaa cccggccggca tcttgatgag agcttacggg 3600
 5 tacggccata aaatcagega agccgttgtt tccctcttaa gcagaaggat ctcgtctgea 3660
 agagtgttgc gcccggattt tgcacccagec aatacagaag tttttgttget gttctccaac 3720
 ttgacaacg gaaagagacc ctctacgtta caccagatga atacaaget gagtgeegtg 3780
 tatggccggag aagccatgca cacggccggg tgcacccat cctacagatg taagagagca 3840
 gacatagcca cgtgcacaga agccgttgcg ttaacgcag ctaacgccc tggaaactgtg 3900
 ggggatggcg tatgcaggc cgtggcgaag aaatggccgt cacecttaa gggagcagca 3960
 10 acaccagtgg gcacaattaa aacagtcatg tgccgtctgt acceccgtcat ccacgctgtg 4020
 geccctaatt tcttcggccac gactgaagcg gaaggggacc gccaatttggc cgctgtctac 4080
 cgggcagtgg cggccaaatg aaacagactg tcactgagca gctgatccat cccgtgtcg 4140
 tccacaggag ttttgcggcgg cggaaagagat aggctgcage aatccctcaa ccatttattt 4200
 acagcaatgg acggccacggc cgtgcacgtg accatctact gcagagacaa aagtggggag 4260
 15 aaaaaaatcc aggaagccat tgacatgagg acggctgtgg agttgtctaa tgatgacgtg 4320
 gagctgacca cagacttggt gagagtgcac ccggacagca gcttggggc tcgtaaaggc 4380
 tacagtacca ctgacgggtc gctgtactcg tactttgaag gtacaaaatt caaccaggct 4440
 getattgata tggcagagat actgacgttgg tggcccaagac tgcacagagc aaacgaacag 4500
 atatgcctat acgcgtggg cggaaacaatg gacaacatca gatccaaatg tccggtgaaac 4560
 20 gattccgatt catcaacacc tccaggaca gtgcctgtcc tttccctcc cgaaataacca ttttagatggg caagttaaaa gcatgggtt gtgtcatct 4680
 ctgttcgacc cgacgggtacc ttcagtgggtt agtccgggaa agtacggcgc atctacgacg 4800
 gaccactcag atccgtcgat aegagggttt gacttggact ggaccacccg ctcgtcttcc 4860
 25 actgcacccg ataccatgtc gctacccagt ttgcagtctgt gtgcacatcg ctcgtatctac 4920
 gacccatgg ctcccatatgt agtgcacggct gacgtacacc ctgaaacccgc aggccatcg 4980
 gacctggggc cagatgtgca ccctgaaaccc cttggccccc gggggccggg gggccgggt 5040
 ctccacccgc gccccaaagag agetgcatac aggactgtt ttagaaacaa gctgcctttg 5160
 30 cccggccggc gaaagccgc acgttggggc gctgtccccca gatgcgttgg cttccgggat tacttccgga 5220
 acgttggggc actttgacca gcaacgggtc gatgggtgtcat atttttctc eteggacact 5280
 gatccgtcg aegtcgtcg actaggccggc ggggggtgtcat atttttctc eteggacact 5340
 ggcacgggac atttacaaca aaaatccgtt aggacgcaca atctccatgt cgcacaactg 5400
 gatgcgttcc aggaggagaa aatgtaccccg caaaaatgg atactgagag ggagaagctg 5460
 ttgtctgtca aatgcacat gcaacccatcg gaggtataa agatgcata ccagtctcg 5520
 35 aaagtggaga acatgaaagc cacgggtgggt gacaggtca catcgccggc cagattgtac 5580
 acgggacgg acgttagccg cataccaaca taccgggttc ggttaccccg cccgtgtac 5640
 tcccttaccc tgatgaaag atttcaagc cccgtatgtt caatcgacg gtgcacacgaa 5700
 tacctatcca gaaattaccc aacagtggcg tgcgttccca taacagatga atacgacgca 5760
 tacttggaca tgggttgcgg gtcggatagt tgcttggaca gagggacatt ctggccggc 5820
 40 aagctccggt gtcacccatgc acatcatgcg taccacccagc cgactgtacg cagtggccgtc 5880
 cggccatccct ttcagaaacac actacagaac gtgttgcgg ccgcacccaa gagaaactgc 5940
 aacgttcacgc aaatgcgaga actacccacc atggacttgg cagtgttcaatgttgc 5940
 ttcaagcgct atgcctgtcc cggagaatat tggaaagaaat atgttacccaa acctatccgg 6000
 ataaccactg agaacatcac taccttatgtg accaaaatgg aaggccggaa agtgcgttgc 6060
 45 ttgtctgtca agacccacaa ctgggttccg ctgcaggagg ttcccatggc cagattcaacg 6120
 gtcgacatga aacgagatgt caaagtgcact ccaggacgc aacacacaga gaaaagaccc 6180
 aaagtccagg taattcaacg agccggacca ttggccaccc cttacccatgttgc 6240
 agggaaattttag taaggagact aatgttgcgtt ttcacccatgttgc acgtgcacac attgtttgtat 6300
 atgtccggcgg aagacttttga cgcgcacatgc gcttccatgttccatccacccagg agacccgggtt 6360
 50 ctagagacgg acattgcac attgcacaaa agccaggacg acttccgttgc ttttacatgttgc 6420
 ttaatgtatcc tcaagatcttccatggat cgttccatgttgc tggacttgc tggacttgc 6480
 tttggggaaa tateccatgt tcaacccatggat actggccacgc gtttcaatgttgc 6540
 atgaaatccgg gcatgttttct gactttttt attaacaatgt ttttgcacat cccatcgac 6600
 agcagggttac tggaggcagag actcaactgac tccggccatgttgc gtttcaatgttgc 6660
 55 aacatcgatcc acggaggatgt ctccgacaaatg ctgtatgggggg aggggtgcgc gtcgtgggtc 6720
 aacatggagg tgaagatcat tgaacgttgc atggggaaa aaccccccata tttttgtgg 6780
 ggattcatag tttttgcacatgc acggccatgtcc gtgtttcaga cccacttaag 6840
 cgcctgttca agttgggtaa gccgttcaaca gtcgttgcacatgc agcaggacgaa agacaggcga 6900
 cgagcactga gtgacgaggt tagcaagttgg ttcggacacg gtttggggc cgaactggag 6960

6166c

gtggcaactaa catctaggta tgaggttagag ggctgcaaaaa gtatccat agccatggcc 7020
accttggcga gggacattaa ggctttaag aaattgagag gacctttat acacctctac 7080
gggggttcca gattggtgcg ttaatacaca gaattctgat tggatcatag cgcaactatta 7140
taggateccag atccccggta attaattgaa ttacatccc acgeaaacgt tttacggccg 7200
5 cccgtggcgc cccggcccg cgccccgtcc ttggccgtt cagggccactc cgggtggctcc 7260
cgtegtcccc gacttccagg cccageagat gcagcaactc atcagegecg taaatgcgct 7320
gacaatgaga cagaacgcaa ttgtcttcgc taggcctccc aaaccaaaga agaagaagac 7380
aaccaaaacca aagccgaaaaa cgcagcccaa gaagatcaac gggaaaaacgc agcagcaaaa 7440
gaagaaaagac aagcaagccg acaagaagaa gaagaaaacc gggaaaaagag aaaaatgtg 7500
10 catgaagatt gaaaatgact gtatcttctgt atgcccgtt ccacagtaac gtagtgtttc 7560
cagacatgtc gggcacccgca ctatcatggg tgcagaaaaat ctgggggtt ctggggggct 7620
tgcataatcg cgctatctcg gtgtctgggtt tggtcacttg cattgggtc cgcagataag 7680
ttagggttagg caatggcatt gatatacgaa gaaaattgaa aacagaaaaa gttagggtaa 7740
15 gcaatggcat ataaccataa ctgtataact tgcataacaaag cgcacacaaga cctgcgeaat 7800
tggcccccgtg gtccgcctca cgaaaaactcg gggcaactca tattgacaca ttaattggca 7860
ataattggaa gcttacataa gcttaattcg acgaaataatt ggatttttat ttattttgc 7920
aattggtttt taatatttcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7980
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ctagegggtc ggcacatggcat ctccacctcc 8040
tegcggtccg acctggccat ccgaaggagg acgcacgtcc acteggatgg ctaagggaga 8100

20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/01064

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 6	C12N15/86	C12N15/45	C07K14/135	C07K14/115
				A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23 ---	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22 ---	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document ---	1-36
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

23 April 1999

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/01064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document ---	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ---	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999 cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9640945	A 19-12-1996	AU 695527	B	13-08-1998
		AU 6117696	A	30-12-1996
		CA 2223610	A	19-12-1996
		EP 0832253	A	01-04-1998
		US 5843913	A	01-12-1998
		US 5880104	A	09-03-1999
WO 9527044	A 12-10-1995	AU 699384	B	03-12-1998
		AU 2155795	A	23-10-1995
		CA 2184261	A	12-10-1995
		EP 0753053	A	15-01-1997
		FI 963860	A	27-09-1996
		JP 9511143	T	11-11-1997
WO 9617072	A 06-06-1996	AU 4594996	A	19-06-1996
		EP 0797679	A	01-10-1997
		US 5814482	A	29-09-1998
		US 5843723	A	01-12-1998
		US 5789245	A	04-08-1998
WO 9911808	A 11-03-1999	NONE		